PRIOR AUTHORIZATION CHECKLIST

Yutrepia™ (treprostinil) inhalation powder

Consider the following Prior Authorization (PA) criteria for YUTREPIA™ (treprostinil) inhalation powder when preparing to submit a PA on behalf of your patient.

DIAGNOSTIC TESTS

☐ Right Heart Catheterization (RHC) with hemodynamic measurements – including documented administration of vasoreactivity test.

Hemodynamic characteristics of pulmonary hypertension	2022 ESC/ERS guidelines	prior to 2022*
Mean pulmonary arterial pressure (mPAP)	>20mm Hg	>25mm Hg
Pretreatment pulmonary capillary wedge pressure (PCWP)	≤15mm Hg	≤15mm Hg
Pulmonary vascular resistance (PVR)	>2 WU	>3 WU

*Earlier numbers are provided for insurance companies that have not adopted the new 2022 guidelines.
WU=wood units

☐ Echocardiogram

☐ High Resolution CT Scan (not required for PAH patients)

Indicate a medical reason if a test was not performed.

YUTREPIA DOSE INFORMATION

☐ Provide the starting dose and each individual maintenance dose, or dose capsule combination, to ensure all doses will be approved.

YUTREPIA QID Doses (mcg)							
26.5	53	79.5	106	132.5	159	185.5	212
				53 + 79.5	79.5 + 79.5	79.5 + 106	106 + 106
				Capsule Combinations (mcg)			

CURRENT AND PREVIOUS THERAPIES

☐ Provide record of current and previous prescription medications, including free samples or vouchers. Drug names, strength and therapy duration are required, as well as any therapeutic problems, such as adverse events or suboptimal product efficacy.

SUPPORTING DOCUMENTATION

☐ Clinical notes documenting the diagnosis of PAH WHO Group 1 or PH-ILD WHO Group 3

☐ YUTREPIA Prescribing Information to detail efficacy, safety and appropriateness

ICD-10 CODE (2024)

Be sure to include all applicable ICD-10 codes based on patient's clinical history and diagnosis.

For PAH Patients

☐ ICD-10 I27.0 Primary pulmonary hypertension
☐ ICD-10 I27.2 Other secondary pulmonary hypertension
☐ Other ICD-10: _____ _____

For PH-ILD Patients

PH:

☐ ICD-10 I27.23 Pulmonary hypertension due to lung diseases and hypoxia
☐ Other ICD-10: _____ _____

ILD IIP:

☐ ICD-10 J84.10 Pulmonary fibrosis, unspecified
☐ ICD-10 J84.111 Idiopathic interstitial pneumonia, NOS
☐ ICD-10 J84.112 Idiopathic pulmonary fibrosis

CTD-related ILD:

☐ ICD-10 M34.81 Systemic sclerosis with lung involvement

Environmental/Occupational Lung Disease:

☐ ICD-10 J61 Pneumoconiosis due to asbestos and other mineral fibers
☐ ICD-10 J67.9 Hypersensitivity pneumonitis due to unspecified dust

Other Causes:

☐ ICD-10 J17 Pneumonia in disease classified elsewhere

ADDITIONAL INFORMATION

☐ WHO or NYHA Functional Class (I-IV)
☐ 6 Minute Walk Distance (6MWD) results

REMINDER

☐ Ensure all questions on the PA form are answered and clinical documentation is included to help avoid a PA denial or delay in processing

☐ Prescriber must sign and date PA form

☐ Request an expedited/urgent review if prescriber certifies that waiting for a standard review could seriously harm the patient's life, health or ability to regain maximum function

If your PA or appeal is denied, please contact your Territory Account Manager (TAM) for additional resources.

Please see reverse for Important Safety Information and accompanying full Prescribing Information for YUTREPIA.

Liquidia™

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

YUTREPIA™ (treprostinil) is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- Treprostinil may cause symptomatic hypotension.
- Treprostinil inhibits platelet aggregation and increases the risk of bleeding.
- Dosage adjustments may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
- May cause bronchospasm.
- Patients with a history of hyperreactive airway disease may be more sensitive.

DRUG INTERACTIONS

- Dosage adjustments may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

USE IN SPECIFIC POPULATIONS

- Safety and effectiveness in pediatric patients have not been established.
- It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
- There are no adequate and well-controlled studies with YUTREPIA in pregnant women.
- There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.
- Treprostinil has not been studied in patients with severe hepatic insufficiency.

ADVERSE REACTIONS

- Most common adverse reactions with YUTREPIA (≥10%) are cough, headache, throat irritation, and dizziness.

Please see accompanying full Prescribing Information for YUTREPIA.

 US-YUTR- 2400012 (05-2025)